Channel Therapeutics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHRO research report →
About the company
Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1. 7 sodium ion-channel, in addition to other related receptors within the broader NaV family.
- CEO
- Francis Knuettel II,
- IPO
- 2024
- Employees
- 4
- HQ
- Freehold, NJ, US
Price Chart
- Market Cap
- $8.90M
- P/E
- -0.05
- P/S
- 0.32
- P/B
- 0.13
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
- Gross Margin
- -0.70%
- Op Margin
- -80.39%
- Net Margin
- -186.23%
- ROE
- -164.11%
- ROIC
- -16.18%
- Revenue
- $16.80M · 0.00%
- Net Income
- $-43,319,000 · -444.53%
- EPS
- $-23.04 · -1511.19%
- Op Income
- $0
- FCF YoY
- -291.70%
- 52W High
- $54.29
- 52W Low
- $1.23
- 50D MA
- $12.03
- 200D MA
- $12.00
- Beta
- 3.29
- Avg Volume
- 111.31K
Get TickerSpark's AI analysis on CHRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 11, 25 | Simmons Chia-Lin | other | 25,000 |
| Apr 11, 25 | Francis Knuettel II | other | 53,988 |
| Nov 13, 24 | Davis Todd C | other | 49,605 |
| Nov 13, 24 | Malamut Richard | other | 24,533 |
| Nov 13, 24 | Friedberg Ezra M | other | 24,533 |
| Sep 12, 24 | Malamut Richard | buy | 10,400 |
| Sep 13, 24 | Francis Knuettel II | buy | 3,500 |
| Sep 12, 24 | Francis Knuettel II | buy | 1,700 |
| Sep 11, 24 | Francis Knuettel II | buy | 5,500 |
| Sep 10, 24 | Francis Knuettel II | buy | 6,500 |
Our CHRO coverage
Recent articles, reports, and earnings notes.
No research on CHRO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHRO report →Similar companies
Peers in the same neighborhood.